Tests a spray to reduce opioid use and pain
Part of Pain clinical trials.
This early trial studies whether Syntocinon can lower pain and help reduce how much opioids people use. It checks safety and the best dose by giving participants the study drug under close medical monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can speak and understand English well enough for study visits
- You currently use opioids recreationally
- Your current weight is within 20% of your “ideal” weight
- You have not had chronic pain (no pain on most days for the past 3 months)
- Your blood pressure, heart rate, and EKG (heart test) must be in safe ranges
- Your blood tests should not show major health problems that make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether oxytocin (a hormone-like medication) can reduce how “appealing” opioids feel and also reduce pain. It’s aimed at older adults who have used opioids before but are not currently dealing with chronic pain most days.
This study tests if a nasal spray containing oxytocin (a natural hormone) can help reduce pain and speed up recovery after pituitary surgery. It may help patients who are having their first pituitary surgery and meet the health requirements listed below.
This study tests a low-dose form of buprenorphine (a medicine for pain) placed inside the cheek. It is designed for people who have never taken opioids before, to see how well it works for pain and how likely it is to be misused.
This early-phase study looks at whether opioid system signals change how people feel pain and respond to feeling socially rejected, like after a breakup. It may help researchers understand why some people experience stronger pain or stress in response to rejection.
This trial tests a pain medicine called oxycodone for patients on breathing machines in the ICU. It aims to see if it provides safe and effective long-term pain control.
This early-phase study tests whether a spray of oxytocin in the nose can be given safely and may affect symptoms in people with arginine-vasopressin deficiency. You might qualify if your hormone levels are stable and you can safely take the nasal study medicine during the study period.
Hear when a new Pain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.